Honokiol: A potent chemotherapy candidate for human colorectal carcinoma

Cancer Institute, Second Affiliated Hospital of Zhejiang University, Hangzhou 310009, Zhejiang province, China.
World Journal of Gastroenterology (Impact Factor: 2.37). 01/2005; 10(23):3459-63.
Source: PubMed

ABSTRACT To investigate the anticancer activity of honokiol on RKO, a human colorectal carcinoma cell line in vitro and in vivo, and to evaluate its possible use in clinic.
In vitro anticancer activity of honokiol was demonstrated by its induction of apoptosis in tumor cells. We analyzed cell proliferation with MTT assay, cell cycle with flow cytosmeter, DNA fragment with electrophoresis on agarose gels. To test the mechanism of honokiol-induced apoptosis, Western blotting was used to investigate the factors involved in this process. The pharmacokinetics study of honokiol was tested by high phase liquid chromatography. In in vivo study, Balb/c nude mice were incubated with RKO cells. Honokiol was injected intraperitoneally every other day into tumor bearing Balb/c nude mice.
Our results showed that honokiol induced apoptosis of RKO cells in a time- and dose-dependent manner. At 5-10 microg/mL for 48 h, honokiol induced apoptosis through activating Caspase cascades. Pharmacokinetics study demonstrated that, honokiol could be absorbed quickly by intraperitoneal injection, and maintained in plasma for more than 10 h. In nude mice bearing RKO-incubated tumor, honokiol displayed anticancer activity by inhibiting tumor growth and prolonging the lifespan of tumor bearing mice.
With its few toxicity to normal cells and potent anticancer activity in vitro and in vivo, honokiol might be a potential chemotherapy candidate in treating human colorectal carcinoma.

1 Follower
32 Reads
    • "In an animal model of ovarian cancer, curcumin showed inhibitory effects on tumor growth and angiogenesis (23). Chen et al. (2004) studied the antiangiogenic effect of artesunate (ART), a semisynthetic derivative of artemisinin (isolated from Artemisia annua) in human ovarian cancer cells in nude mice. Tumor growth of 50 mg/kg/day) or 100 mg/kg/day treatment group was reduced by 41% or 62% after 15-day administration of ART. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is the formation of new capillaries from existing vessels. Vascular endothelial growth factor (VEGF) promotes this growth by stimulating endothelial cells, which form vessel walls and transport nutrients and oxygen to tissues. VEGF has been implicated in several diseases, such as cancer and gynecologic disorders. Antiangiogenic agents prevent VEGF from binding to its receptors on the endothelial cell surface, which inhibits vessel development. Antiangiogenic agents have been found to be effective in treating several gynecologic diseases, such as endometriosis and uterine fibroids. Natural products with respect to finding new compounds with antiangiogenic effects are interested. In this review, we have focused on the importance of natural products with antiangiogenic activity in treating some malignant and benign angiogenesis-related gynecological disorders, including endometriosis and uterine fibroids.
    Nutrition and Cancer 01/2014; 66(2). DOI:10.1080/01635581.2014.865136 · 2.32 Impact Factor
  • Source
    • "We used JC-1, which is a widely used probe, to detect the changes of mitochondrial membrane potential (ÄØm) [10,11]. Treatment with Ophiobolin-O (0.1 µM) or ADM (3 µM, 6 µM or 9 µM) did not show a significant decrease in red/green fluorescence ratio. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multidrug-resistance is a major obstacle facing cancer chemotherapy. This paper demonstrates that novel compound Ophiobolin-O reverses MCF-7/ADR resistance to adriamycin (ADM). The IC50 of ADM treated MCF-7 cells was 2.02 ± 0.05 µM and 74.00 ± 0.18 µM treated MCF-7/ADR cells, about 37-fold, compared to the former. However, 0.1 µM Ophiobolin-O (less than 20% inhibition concentration) combined with ADM caused the decreased IC50 of ADM to 6.67 ± 0.98 µM, indicating it reversed ADM resistance of MCF-7/ADR cells (11-fold). Furthermore, Ophiobolin-O increased ADM-induced mitochondrial pathway apoptosis and G2/M phase arrest, which is partly due to the elevation level of ROS in MCF-7/ADR cells. As we described in this paper, the reversal effect of Ophiobolin-O may be due to the reduction of resistance-related protein P-Glycoprotein (P-gp, also known as MDR1) through inhibiting the activity of the multidrug resistance 1 (MDR1) gene promoter, which makes MCF-7/ADR cells more sensitive to ADM treatment. Assays in nude mice also showed that the combination of ADM and Ophiobolin-O significantly improved the effect of ADM.
    Marine Drugs 11/2013; 11(11):4570-84. DOI:10.3390/md11114570 · 2.85 Impact Factor
  • Source
    • "Honokiol, a small molecule biphenolic compound purified from the medicinal herb Magnolia officinalis (Magnoliae Cortex), has been known to exert antithrombotic, antibacterial and anxiolytic effects (6–9). Studies have revealed that honokiol is able to inhibit tumor growth in animals and induce apoptosis in various types of cancer cells, including leukemia, hepatoma, prostate, lung and colon cells (10–13). More recently, honokiol has been shown to be capable of crossing the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) and inhibiting brain tumor growth in the human U251 xenograft glioma model (14). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Honokiol, a hydroxylated biphenyl compound isolated from the Chinese herb Magnolia officinalis, has been reported to have anticancer activities in a variety of cancer cell lines. The present study aimed to evaluate the anticancer effect and possible molecular mechanisms of honokiol in a glioblastoma multiforme (GBM) cell line. The anticancer activities of honokiol were investigated in the DBTRG-05MG GBM cell line. The effect of honokiol on cell growth was determined using a sulforhodamine B assay. Flow cytometry and immunoblotting were used to measure honokiol-induced apoptosis (programmed cell death type I) and autophagy (programmed cell death type II). Honokiol was observed to reduce DBTRG-05MG cell viability in a dose-dependent manner. At a dose of 50 μM, honokiol markedly decreased the expression of Rb protein and led to the cleavage of poly(ADP-ribose) polymerase and Bcl-xL to promote apoptosis in the cancer cells. In addition, markers of autophagy, including Beclin-1 and LC3-II, were also significantly increased. In addition to apoptosis, honokiol was also able to induce autophagy in the DBTRG-05MG cells. The mechanisms that are responsible for the correlation between honokiol-induced apoptosis and autophagy require further investigation. Such efforts may provide a potential strategy for improving the clinical outcome of GBM treatment.
    Oncology letters 11/2013; 6(5):1435-1438. DOI:10.3892/ol.2013.1548 · 1.55 Impact Factor
Show more


32 Reads
Available from